About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD2.26
- USD2.55
- USD2.23
- USD4.07
- -15.60%
- --
- 295.27k
- 672.61k
- 101M
- 1.24
- -24.90%
Stock News
1 hour ago
Trump VP contender Kristi Noem stands by killing her dog Cricket amid bipartisan ridicule
CNBC
2 hours ago
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
Yahoo
3 hours ago
Does the TikTok Ban Make Alphabet Stock a Buy?
Yahoo
3 hours ago
Could Salesforce Stock Help You Become a Millionaire?
Yahoo
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
